SLC5A2 and heart failure: Although recent real-world data show gradual adoption, the Get With The Guidelines—Heart Failure registry (July 2021 to June 2022) reported that only 20.2% of eligible heart failure patients were discharged with SGLT2 inhibitors, reflecting a limited uptake despite guideline endorsement [47].